P099 Effect of a mucolytic agent delivered through sinus pulsating aerosol system (SPAS) device on sinonasal symptoms and patient report outcomes in people with cystic fibrosis (PwCF)

M.N Balaguer Cartagena,R Mellidez Acosta,A Garcia Piñero,M.J Selma Ferrer,P García Díaz,J.P Reig Mezquida,I Pérez Muñoz,A Solé Jover

doi:10.1016/s1569-1993(23)00474-5

P099 Effect of a mucolytic agent delivered through sinus pulsating aerosol system (SPAS) device on sinonasal symptoms and patient report outcomes in people with cystic fibrosis (PwCF)

M.N Balaguer Cartagena, R Mellidez Acosta + Show 6 more

https://doi.org/10.1016/s1569-1993(23)00474-5

Copy DOI

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Publication Date: Jun 1, 2023

Affiliation: Hospital Universitari i Politècnic La Fe

#People With Cystic Fibrosis #Upper Airway + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objectives: Upper airway (UAW) obstruction is not usually assessed in the routine care of chronic rhinosinusitis (CRS) in PwCF. SPAS device produces a pulsatile aerosol that deposits approximately 28 times more drugs in the paranasal cavities than a nasal spray. The aim of our study is to evaluate the effect of 6% mucochlear solution administered by SPAS on CPP and CRS.

Full Text